ClinicalTrials.gg
CompletedNCT03846310ARC-4Updated Dec 9, 2024

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

A Phase 1 interventional study of Etrumadenant and Zimberelimab in Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer and Nonsquamous Nonsmall Cell Neoplasm of Lung, sponsored by Arcus Biosciences, Inc.. Completed at 22 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by Arcus Biosciences, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
77
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 6 under way, 2 of them phase 3. zimberelimab · Carcinoma, Non-Small-Cell Lung.

Enrollment
8th of 10
77 · median 152
Started
2019
the only one that year
Phase 1
3 of 10
1 open now
Registered
2nd of 10
by date
Lead sponsor
4 of 10
Arcus Biosciences, Inc.

Among the 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung, this one is the 8th largest by enrollment, is the only one that started in 2019, is one of 3 in phase 1, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About zimberelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical activity of etrumadenant (AB928) in combination with carboplatin and pemetrexed, with or without an anti-PD-1 antibody (pembrolizumab or zimberelimab), in participants with non-squamous Non-Small Cell Lung Cancer (NSCLC).

Read the detailed description

In the dose-escalation phase, escalating doses of etrumadenant in combination with carboplatin and pemetrexed at standard doses (Arm A), and etrumadenant in combination with carboplatin, pemetrexed and pembrolizumab (Arm B), may be assessed in participants with advanced NSCLC. Eligible participants will receive oral administration of etrumadenant as well as IV infused carboplatin, pemetrexed, with or without pembrolizumab in this phase. The recommended dose for expansion (RDE) of etrumadenant will be determined upon completion of the dose-escalation phase.

In the dose-expansion phase, zimberelimab in combination with carboplatin and pemetrexed (Arm 1), and etrumadenant at RDE in combination with carboplatin, pemetrexed, and zimberelimab (Arm 2) may be assessed in eligible NSCLC participants who harbor an EGFR mutation and have progressed on EGFR Tyrosine Kinase Inhibitor (TKI) treatment(s).

Overall duration of treatment will depend on how well the treatment is tolerated.

Treatment may continue until unacceptable toxicity or progressive disease or other reasons specified in the protocol.

03

Conditions studied

  • Non Small Cell Lung Cancer Metastatic
  • Non Small Cell Lung Cancer
  • Nonsquamous Nonsmall Cell Neoplasm of Lung
  • Sensitizing EGFR Gene Mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants; age ≥ 18 years
  • confirmed nonsquamous NSCLC that is , locally advanced, or recurrent with progression
  • Arm A participants must fulfill one of the following:

    • Participant has a genetic alteration (mutation or rearrangement) and has received all available targeted therapy. Previous treatment with chemotherapy or /-L1 therapy is not allowed.
    • Participant has not received any therapy for the disease under study and standard therapy is refused.
    • Participant has progressed on PD-1/-L1 therapy (monotherapy or combination regimen). Previous treatment with chemotherapy is not allowed.
    • Participant has progressed on PD-1/-L1 therapy (monotherapy or combination regimen) and has received less than 4 cycles of carboplatin/pemetrexed and further chemotherapy is appropriate.
    • Participant has received any number of prior treatments and is without alternative or curative therapy.
  • Arm B participants must fulfill one of the following:

    • Participant has a genetic alteration (mutation or rearrangement) and has received all available targeted therapy. Previous treatment with chemotherapy or PD-1/-L1 therapy is not allowed.
    • Participant has not received any therapy for the disease under study and standard therapy is refused.
    • Participant has received any number of prior treatments and is without alternative or curative therapy.
  • Arm 1 and Arm 2 participants must have a sensitizing epidermal growth factor receptor (EGFR) mutation with disease progression or treatment intolerance after one or more approved TKIs. Previous treatment with chemotherapy or PD-1/L-1 therapy is not allowed.
  • No TKI therapy within 5 days of Cycle 1 Day 1
  • The last dose of previous therapy is at least 4 weeks or 5 half-lives prior to Cycle 1 Day 1.
  • Must have at least 1 per (RECIST v1.1)
  • (ECOG) performance status score of 0 or 1.
  • Confirm that an sample is available and ≤ 24 months old; if not, a new biopsy of a tumor lesion should be obtained at screening
  • Adequate organ and marrow function

Exclusion criteria

Exclusion Criteria:

  • Use of any against infectious diseases within 4 weeks (28 days) of initiation of product
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the pre-screening or screening visit through 30 days after the last dose of etrumadenant, 90 days after the last dose of zimberelimab or pembrolizumab, or 6 months after the last dose of pemetrexed, whichever is longer
  • Any active disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, , or drugs), except for vitiligo or resolved childhood asthma/atopy
  • Prior active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer
  • Prior use of an adenosine pathway targeting agent
  • Due to potential for drug-drug interactions with etrumadenant, participants must not have had:

    • Treatment with breast cancer resistance protein substrates or P-glycoprotein with a narrow therapeutic window, administered orally within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment.
    • Treatment with known strong cytochrome P450 3A4 () inducers and strong CYP3A4 inhibitors within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Dose Escalation Arm A

    Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer.

    Drug: Etrumadenant · Drug: Carboplatin · Drug: Pemetrexed

  • Experimental
    Dose Escalation Arm B

    Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen and pembrolizumab in participants with Non-Small Cell Lung Cancer.

    Drug: Etrumadenant · Drug: Carboplatin · Drug: Pemetrexed · Drug: Pembrolizumab

  • Experimental
    Dose Expansion Arm 1

    Zimberelimab will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.

    Drug: Zimberelimab · Drug: Carboplatin · Drug: Pemetrexed

  • Experimental
    Dose Expansion Arm 2

    The etrumadenant at RDE determined from the dose escalation phase will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen and zimberelimab in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.

    Drug: Etrumadenant · Drug: Zimberelimab · Drug: Carboplatin · Drug: Pemetrexed

Interventions

  • Etrumadenant is an A2aR and A2bR antagonist

    Also known as: AB928

  • Zimberelimab is a fully human anti-PD-1 monoclonal antibody

    Also known as: AB122

  • Carboplatin administered as part of standard chemotherapy regimen

  • Pemetrexed administered as part of standard chemotherapy regimen

  • Pembrolizumab is a humanized anti-PD-1 monoclonal antibody

06

What researchers measure

Primary outcomes

  1. Percentage of participants with Adverse Events

    Time frame: From first study treatment administration until up to 90 days after the last dose (Approximately 1 year)

  2. Percentage of participants who experience a Dose Limiting Toxicity

    Time frame: From first study treatment administration through Day 21

Secondary outcomes

  1. Percentage of participants with anti-drug antibodies to zimberelimab

    Time frame: Recorded at baseline (screening), during the first 4 cycles of treatment (4 months) and 30 days post last dose (i.e. in total approximately 5 months).

  2. Plasma concentration of etrumadenant

    Time frame: Recorded at baseline (screening), during the first 4 cycles of treatment (4 months) and 30 days post last dose (i.e. in total approximately 5 months).

  3. Serum concentration of zimberelimab

    Time frame: Recorded at baseline (screening), during the first 4 cycles of treatment (4 months) and 30 days post last dose (i.e. in total approximately 5 months).

  4. Progression Free Survival (PFS)

    Time frame: From start of treatment up to the first occurrence of progressive disease or death from any cause, whichever occurs first (up to approximately 3-5 years)

  5. Duration of Response

    Time frame: From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)

  6. Percentage of Participants with Disease Control (complete response, partial response, or stable disease) for >6 months

    Time frame: From study enrollment until disease progression or loss of clinical benefit (up to approximately 3-5 years)

  7. Percentage of participants with Objective Response

    Time frame: From study enrollment until participant discontinuation, first occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 3-5 years)

07

Study locations

22 sites
  • Arizona Cancer Research Center (ACRC)
    Tucson, Arizona 85715, United States
  • SCRI Florida Cancer Specialists - South
    Fort Myers, Florida 33901, United States
  • SCRI Florida Cancer Specialists - North
    Tavares, Florida 33705, United States
  • SCRI Tennessee Oncology - Nashville
    Nashville, Tennessee 37203, United States
  • USO Texas Oncology - Dallas (Baylor Charles A. Sammons Cancer Center)
    Dallas, Texas 75246, United States
  • USO Virginia Cancer Specialist
    Fairfax, Virginia 22031, United States
  • USO Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Medical Oncology Associates/Summit Cancer Center
    Spokane, Washington 99208, United States
  • The Catholic University of Korea St. Vincent Hospital
    Suwon-si, Gyeonggi 16247, Korea, Republic of
  • Chungbuk National University Hospital
    Cheongju-si, 28644, Korea, Republic of
  • Bundang CHA Medical Center
    Seongnam-si, 13496, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 3722, Korea, Republic of
  • Asan Medical Centre
    Seoul, 5505, Korea, Republic of
  • Seoul St. Mary's Hospital
    Seoul, 6591, Korea, Republic of
  • Seoul National University Hospital
    Suwon, 3080, Korea, Republic of
  • National University Hospital
    Singapore, 119228, Singapore
  • National Cancer Centre Singapore
    Singapore, 169610, Singapore
  • Changhua Christian Hospital
    Changhua, 500, Taiwan
  • Taipei Medical University - Shuang Ho Hospital
    New Taipei City, 23561, Taiwan
  • Chi Mei Hospital, Liouying
    Tainan City, 73657, Taiwan
  • National Taiwan University Hospital
    Taipei City, 10002, Taiwan
  • Tri Service General Hospital
    Taipei City, 11490, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. For more information, please visit our website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Data sharing details ↗ · trials.arcusbio.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Nov 2024, 67 months.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 67 months is above that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2019
First posted
Feb 19, 2019
StartActual
Apr 1, 2019
Primary completionActual
Nov 18, 2024
CompletionActual
Nov 18, 2024
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03846310
Collaborators
Gilead Sciences
Responsible party
Sponsor
First posted
Feb 19, 2019
Start date
Apr 1, 2019
Primary completion
Nov 18, 2024
Completion
Nov 18, 2024
Last update
Dec 9, 2024

Study contacts

Medical Director
study director · Arcus Biosciences, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AB928 · Zimberelimab

Start the discussion